Choosing antithrombotic treatment for high-risk patients with non-ST-elevation acute coronary syndrome;Elección del tratamiento antitrombótico en pacientes con síndrome coronario agudo sin elevación del segmento ST de alto riesgo

Revista Espanola de Cardiologia Suplementos

Volumn 5, Issue C, 2005, Pages

  Bueno, Héctor ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Antithrombotic therapy; Clopidogrel; Glycoprotein IIb IIIa inhibitor; High risk; Non ST elevation acute coronary syndrome

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; NITRATE; PLACEBO; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; BLEEDING; CARDIAC PATIENT; CHRONIC KIDNEY FAILURE; CORONARY STENT; DIABETES MELLITUS; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; INVASIVE PROCEDURE; MEDICAL DECISION MAKING; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; REVIEW;

EID: 35948938552     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1131-3587(05)74111-X     Document Type: Article

References (30)

1. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337:447-52.
2. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593-601.
3. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-43.
4. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498-505.
5. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms. N Engl J Med. 1998;338:1488-97.
6. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
7. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J. 2002;23:1809-40.
8. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman J, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366-74.
9. López Bescós L, Arós Borau F, Lidón Corbi RM, Cequier Fillat A, Bueno H, Alonso JJ, et al. Actualización (2002) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en angina inestable/infarto sin elevación del segmento ST. Rev Esp Cardiol. 2002;55:631-42.
10. Bueno H. Introducción: puntos clave en el manejo del SCASEST. Rev Esp Cardiol. 2005; 56 Supl: cita cruzada.
11. Bueno H, Bardají A, Fernández Ortiz A, Marrugat J, Martí H, Heras M, en nombre de los investigadores del Estudio DESCARTES. Descripción del Estado de los Síndromes Coronarios Agudos en un Registro Temporal ESpañol. Estudio DESCARTES. Rev Esp Cardiol. 2005;58:242-50.
12. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J. 2005;26:804-47.
13. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004;110:1202-8.
14. Garcia S, Canoniero MJ, Chirinos JA, De Marchena E, Salerno T, Ferreira A. Development of a score to predict the need for coronary artery bypass graft surgery in patients with non-ST segment elevation acute coronary syndromes. Ann Thorac Surg. 2004;78:2022-6.
15. Barrabés JA, Figueras J, Moure C, Cortadellas J, Soler-Soler J. Prognostic value of lead aVR in patients with a first non-ST-segment elevation acute myocardial infarction. Circulation. 2003;108:814-9.
16. Budaj A, Yusuf S, Mehta SR, Fox KA, Tognoni G, Zhao F, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation. 2002;106:1622-6.
17. Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL, et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoPro Give Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol. 2003;42:1188-95.
18. Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, Ten Berg JM, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 2004;350:232-8.
19. Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, Montalescot G, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24:1815-23.
20. Collet JP, Montalescot G, Agnelli G, Van de Werf F, Gurfinkel EP, López-Sendón J, et al. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J. 2005;2 [Epub ahead of print].
21. Quiles J, Avanzas P, Bueno H. Fatal retroperitoneal haemorrhage associated with enoxaparin and impaired renal function. Int J Cardiol. 2005 28;98:523-4.
22. Green B, Greenwood M, Saltissi D, Westhuyzen J, Kluver L, Rowell J, et al. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol. 2005;59:281-90.
23. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J. 2003;146:33-41.
24. Hasdai D, Holmes DR, Criger DA, Topol EJ, Califf RM, Harrington RA, for the PURSUIT trial investigators. Age and outcome after acute coronary syndromes without persistent ST-segment elevation. Am Heart J. 2000;139:858-66.
25. Januzzi JL, Sabatine MS, Wan Y, Servoss SJ, DiBattiste PM, Jang IK, et al. Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy. Am J Cardiol. 2003;91:457-61.
26. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189-98.
27. Théroux P, Alexander J, Pharand C, Barr E, Snapinn S, Ghannam AF, et al. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study. Circulation. 2000;102:2466-72.
28. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000;35:922-8.
29. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndromes. Circulation. 2001;104:2767-71.
30. Sabatine MS, Braunwald E. Will diabetes save the platelet blockers? Circulation. 2001;104:2759-61.